{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:26:29Z","timestamp":1648668389147},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11910-006-0019-6","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T15:07:13Z","timestamp":1180105633000},"page":"281-286","source":"Crossref","is-referenced-by-count":5,"title":["Update on huntington\u2019s disease"],"prefix":"10.1007","volume":"6","author":[{"given":"Sarah B.","family":"Berman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Timothy","family":"Greenamyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"19_CR1","first-page":"212","volume-title":"Parkinson\u2019s Disease and Movement Disorders","author":"KM Biglan","year":"2002","unstructured":"Biglan KM, Shoulson I: Huntington\u2019s disease. In Parkinson\u2019s Disease and Movement Disorders. Edited by Jankovic J, Tolosa E. Philadelphia: Lippincott Williams & Wilkins; 2002:212\u2013227."},{"key":"19_CR2","doi-asserted-by":"crossref","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 1993, 72:971\u2013983.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000072863","volume":"100","author":"MA Hickey","year":"2003","unstructured":"Hickey MA, Chesselet MF: The use of transgenic and knock-in mice to study Huntington\u2019s disease. Cytogenet Genome Res 2003, 100:276\u2013286.","journal-title":"Cytogenet Genome Res"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","volume":"20","author":"SH Li","year":"2004","unstructured":"Li SH, Li XJ: Huntingtin-protein interactions and the pathogenesis of Huntington\u2019s disease. Trends Genet 2004, 20:146\u2013154.","journal-title":"Trends Genet"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0031-6865(95)00003-R","volume":"69","author":"MF Perutz","year":"1995","unstructured":"Perutz MF: Polar zippers: their role in human disease. Pharm Acta Helv 1995, 69:213\u2013224.","journal-title":"Pharm Acta Helv"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1097-2765(00)80059-3","volume":"1","author":"P Kahlem","year":"1998","unstructured":"Kahlem P, Green H, Djian P: Transglutaminase action imitates Huntington\u2019s disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1998, 1:595\u2013601.","journal-title":"Mol Cell"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao M, Ambrose C, Myers R, et al.: Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat Genet 1993, 4:387\u2013392.","journal-title":"Nat Genet"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, et al.: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990\u20131993.","journal-title":"Science"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O","volume":"46","author":"S Kuemmerle","year":"1999","unstructured":"Kuemmerle S, Gutekunst CA, Klein AM, et al.: Huntington aggregates may not predict neuronal death in Huntington\u2019s disease. Ann Neurol 1999, 46:842\u2013849.","journal-title":"Ann Neurol"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","volume":"292","author":"NF Bence","year":"2001","unstructured":"Bence NF, Sampat RM, Kopito RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552\u20131555. This shows that mutant huntingtin inhibits the ubiquitin-proteasome system, suggesting a role for abnormal protein processing in HD.","journal-title":"Science"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","volume":"11","author":"B Ravikumar","year":"2002","unstructured":"Ravikumar B, Duden R, Rubinsztein DC: Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002, 11:1107\u20131117. This proposes a potential role for authophagic degradation in the pathogenesis of HD.","journal-title":"Hum Mol Genet"},{"issue":"Suppl 4","key":"19_CR12","doi-asserted-by":"crossref","first-page":"16412","DOI":"10.1073\/pnas.182426899","volume":"99","author":"H Sakahira","year":"2002","unstructured":"Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU: Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc Natl Acad Sci U S A 2002, 99(Suppl 4):16412\u201316418.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1523\/JNEUROSCI.3001-05.2005","volume":"25","author":"VM Miller","year":"2005","unstructured":"Miller VM, Nelson RF, Gouvion CM, et al.: CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 2005, 25:9152\u20139161.","journal-title":"J Neurosci"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1073\/pnas.0505801102","volume":"102","author":"A Iwata","year":"2005","unstructured":"Iwata A, Christianson JC, Bucci M, et al.: Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci U S A 2005, 102:13135\u201313140.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","volume":"23","author":"JH Cha","year":"2000","unstructured":"Cha JH: Transcriptional dysregulation in Huntington\u2019s disease. Trends Neurosci 2000, 23:387\u2013392.","journal-title":"Trends Neurosci"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.cell.2005.10.030","volume":"123","author":"W Zhai","year":"2005","unstructured":"Zhai W, Jeong H, Cui L, et al.: In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005, 123:1241\u20131253. This reports an elegant system to analyze effects of mutant huntingtin on transcriptional repression. They show that effects are polyQ length-dependent and that soluble mutant huntingtin fragments can affect transcriptional regulation.","journal-title":"Cell"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mcn.2005.05.003","volume":"30","author":"SY Cong","year":"2005","unstructured":"Cong SY, Pepers BA, Evert BO, et al.: Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 2005, 30:12\u201323.","journal-title":"Mol Cell Neurosci"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/hmg\/11.8.905","volume":"11","author":"ZX Yu","year":"2002","unstructured":"Yu ZX, Li SH, Nguyen HP, Li XJ: Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum Mol Genet 2002, 11:905\u2013914.","journal-title":"Hum Mol Genet"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","volume":"296","author":"AW Dunah","year":"2002","unstructured":"Dunah AW, Jeong H, Griffin A, et al.: Sp1 and TAFII130 transcriptional activity disrupted in early Huntington\u2019s disease. Science 2002, 296:2238\u20132243.","journal-title":"Science"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S0317167100032212","volume":"18","author":"AC Ludolph","year":"1991","unstructured":"Ludolph AC, He F, Spencer PS, et al.: 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991, 18:492\u2013498.","journal-title":"Can J Neurol Sci"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/B:NERE.0000014824.04728.dd","volume":"29","author":"SE Browne","year":"2004","unstructured":"Browne SE, Beal MF: The energetics of Huntington\u2019s disease. Neurochem Res 2004, 29:531\u2013546.","journal-title":"Neurochem Res"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1042\/bss0660055","volume":"66","author":"DG Nicholls","year":"1999","unstructured":"Nicholls DG, Budd SL, Ward MW, Castilho RF: Excitotoxicity and mitochondria. Biochem Soc Symp 1999, 66:55\u201367.","journal-title":"Biochem Soc Symp"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst CA, Leavitt BR, et al.: Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731\u2013736. This showed that polyglutamines can directly act on mitochondria to alter metabolism.","journal-title":"Nat Neurosci"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archneur.62.1.46","volume":"62","author":"S Gunawardena","year":"2005","unstructured":"Gunawardena S, Goldstein LS: Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 2005, 62:46\u201351.","journal-title":"Arch Neurol"},{"key":"19_CR25","doi-asserted-by":"crossref","unstructured":"Chang DT, Rintoul GL, Pandipati S, Reynolds IJ: Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 2006, In press. Links huntingtin aggregates to impaired cellular trafficking and impaired mitochondrial function.","DOI":"10.1016\/j.nbd.2005.12.007"},{"key":"19_CR26","doi-asserted-by":"crossref","unstructured":"Huntington Study Group: A randomized, placebocontrolled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology 2001, 57:397\u2013404.","DOI":"10.1212\/WNL.57.3.397"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","volume":"108","author":"H Ryu","year":"2005","unstructured":"Ryu H, Rosas HD, Hersch SM, Ferrante RJ: The therapeutic role of creatine in Huntington\u2019s disease. Pharmacol Ther 2005, 108:193\u2013207.","journal-title":"Pharmacol Ther"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K, et al.: Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG. Neurology 2006, 66:250\u2013252.","journal-title":"Neurology"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","volume":"65","author":"BK Puri","year":"2005","unstructured":"Puri BK, Leavitt BR, Hayden MR, et al.: Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005, 65:286\u2013292.","journal-title":"Neurology"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","volume":"196","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van RaamsdonkJM, Pearson J, Rogers DA, et al.: Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005, 196:266\u2013272.","journal-title":"Exp Neurol"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"F Giorgini","year":"2005","unstructured":"Giorgini F, Guidetti P, Nguyen Q, et al.: A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005, 37:526\u2013531.","journal-title":"Nat Genet"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0006-3223(95)00377-0","volume":"39","author":"L Vecsei","year":"1996","unstructured":"Vecsei L, Beal MF: Huntington\u2019s disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives. Biol Psychiatry 1996, 39:1061\u20131063.","journal-title":"Biol Psychiatry"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1073\/pnas.0408936102","volume":"102","author":"X Zhang","year":"2005","unstructured":"Zhang X, Smith DL, Meriin AB, et al.: A potent small molecule inhibits polyglutamine aggregation in Huntington\u2019s disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 2005, 102:892\u2013897.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1471-4159.2005.03253.x","volume":"94","author":"C Cleren","year":"2005","unstructured":"Cleren C, Calingasan NY, Chen J, Beal MF: Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 2005, 94:995\u20131004.","journal-title":"J Neurochem"},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pbb.2005.10.018","volume":"82","author":"MG Tadros","year":"2005","unstructured":"Tadros MG, Khalifa AE, Abdel-Naim AB, Arafa HM: Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington\u2019s disease phenotype. Pharmacol Biochem Behav 2005, 82:574\u2013582.","journal-title":"Pharmacol Biochem Behav"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","volume":"22","author":"A Dedeoglu","year":"2002","unstructured":"Dedeoglu A, Kubilus JK, Jeitner TM, et al.: Therapeutic effects of cystamine in a murine model of Huntington\u2019s disease. J Neurosci 2002, 22:8942\u20138950.","journal-title":"J Neurosci"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","volume":"95","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van RaamsdonkJM, Pearson J, Bailey CD, et al.: Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005, 95:210\u2013220.","journal-title":"J Neurochem"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03255.x","volume":"94","author":"JT Pinto","year":"2005","unstructured":"Pinto JT, Van Raamsdonk JM, Leavitt BR, et al.: Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J Neurochem 2005, 94:1087\u20131101.","journal-title":"J Neurochem"},{"key":"19_CR39","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/mds.20589","volume":"20","author":"R Dubinsky","year":"2005","unstructured":"Dubinsky R, Gray C: CYTE-I-HD: Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington\u2019s disease. Mov Disord 2005, 20:1316\u20131322.","journal-title":"Mov Disord"},{"key":"19_CR40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z, et al.: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36:585\u2013595.","journal-title":"Nat Genet"},{"key":"19_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-1","volume":"6","author":"J Wang","year":"2005","unstructured":"Wang J, Gines S, MacDonald ME, Gusella JF: Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci 2005, 6:1.","journal-title":"BMC Neurosci"},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","volume":"413","author":"JS Steffan","year":"2001","unstructured":"Steffan JS, Bodai L, Pallos J, et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739\u2013743.","journal-title":"Nature"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","volume":"23","author":"RJ Ferrante","year":"2003","unstructured":"Ferrante RJ, Kubilus JK, Lee J, et al.: Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice. J Neurosci 2003, 23:9418\u20139427.","journal-title":"J Neurosci"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G Gardian","year":"2005","unstructured":"Gardian G, Browne SE, Choi DK, et al.: Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease. J Biol Chem 2005, 280:556\u2013563.","journal-title":"J Biol Chem"},{"key":"19_CR45","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","volume":"100","author":"E Hockly","year":"2003","unstructured":"Hockly E, Richon VM, Woodman B, et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 2003, 100:2041\u20132046.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR46","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1474-4422(04)00937-8","volume":"3","author":"VW Yong","year":"2004","unstructured":"Yong VW, Wells J, Giuliani F, et al.: The promise of minocycline in neurology. Lancet Neurol 2004, 3:744\u2013751.","journal-title":"Lancet Neurol"},{"key":"19_CR47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","volume":"19","author":"M Thomas","year":"2004","unstructured":"Thomas M, Ashizawa T, Jankovic J: Minocycline in Huntington\u2019s disease: a pilot study. Mov Disord 2004, 19:692\u2013695.","journal-title":"Mov Disord"},{"key":"19_CR48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/01.WNL.0000049936.85487.7A","volume":"60","author":"RM Bonelli","year":"2003","unstructured":"Bonelli RM, Heuberger C, Reisecker F: Minocycline for Huntington\u2019s disease: an open label study. Neurology 2003, 60:883\u2013884.","journal-title":"Neurology"},{"key":"19_CR49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.20564","volume":"58","author":"S Furtado","year":"2005","unstructured":"Furtado S, Sossi V, Hauser RA, et al.: Positron emission tomography after fetal transplantation in Huntington\u2019s disease. Ann Neurol 2005, 58:331\u2013337.","journal-title":"Ann Neurol"},{"key":"19_CR50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1602\/neurorx.1.4.394","volume":"1","author":"SB Dunnett","year":"2004","unstructured":"Dunnett SB, Rosser AE: Cell therapy in Huntington\u2019s disease. NeuroRx 2004, 1:394\u2013405.","journal-title":"NeuroRx"},{"key":"19_CR51","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, et al.: RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 2005, 102:5820\u20135825.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR52","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron E, Denovan-Wright EM, Nash K, et al.: Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice. Mol Ther 2005, 12:618\u2013633.","journal-title":"Mol Ther"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.expneurol.2004.12.009","volume":"193","author":"N Popovic","year":"2005","unstructured":"Popovic N, Maingay M, Kirik D, Brundin P: Lentiviral gene delivery of GDNF into the striatum of R6\/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 2005, 193:65\u201374.","journal-title":"Exp Neurol"},{"key":"19_CR54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.expneurol.2003.09.002","volume":"185","author":"D Zala","year":"2004","unstructured":"Zala D, Bensadoun JC, Pereira de Almeida L, et al.: Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington\u2019s disease transgenic mice. Exp Neurol 2004, 185:26\u201335.","journal-title":"Exp Neurol"},{"key":"19_CR55","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ymthe.2005.04.003","volume":"12","author":"TW Miller","year":"2005","unstructured":"Miller TW, Messer A: Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 2005, 12:394\u2013401.","journal-title":"Mol Ther"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","volume":"102","author":"WJ Wolfgang","year":"2005","unstructured":"Wolfgang WJ, Miller TW, Webster JM, et al.: Suppression of Huntington\u2019s disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A 2005, 102:11563\u201311568.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR57","doi-asserted-by":"crossref","unstructured":"Huntington Study Group: Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366\u2013372.","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"19_CR58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.wnf.0000186648.93612.a5","volume":"28","author":"M Tommaso de","year":"2005","unstructured":"de TommasoM, Di FruscoloO, Sciruicchio V, et al.: Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 2005, 28:280\u2013284.","journal-title":"Clin Neuropharmacol"},{"key":"19_CR59","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.20613","volume":"58","author":"L Brusa","year":"2005","unstructured":"Brusa L, Versace V, Koch G, et al.: Improvement of choreic movements by 1Hz repetitive transcranial magnetic stimulation in Huntington\u2019s disease patients. Ann Neurol 2005, 58:655\u2013656.","journal-title":"Ann Neurol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-006-0019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-006-0019-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-006-0019-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:24:35Z","timestamp":1559435075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-006-0019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11910-006-0019-6","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}